Literature DB >> 6158972

Surface antigens on human melanoma cells studied with heterologous antisera.

G P Roberts.   

Abstract

Antisera were raised in rabbits to 6 human melanoma cell lines. The cell-surface antigens recognized by these antisera were examined using cell-surface labelling with (125)I, followed by immunoprecipitation of soluble extracts of the cells and polyacrylamide-gel electrophoresis of the immunoprecipitates in the presence of sodium dodecyl sulphate (SDS). Up to 16 cell-surface antigens were recognized by these antisera, and 5 of the melanoma cell lines had a similar profile of cell-surface antigens. Digestion of labelled melanoma cells with neuraminidase before immunoprecipitation revealed that 8 of the larger antigens were sialoglycoproteins. The melanoma antisera produced haemagglutination of human erythrocytes at high dilutions, but the antigens involved could not be detected by iodination. In contrast, absorption of the melanoma sera with lymphocytes and fibroblasts revealed that these cells did contain some cell-surface glycoproteins in common with melanoma cells. The melanoma antisera contained antibodies to foetal calf serum proteins, but the amounts of these proteins on the surface of melanoma-cells were very low. Immunoprecipitation of labelled melanoma cell extracts with monospecific antiserum to β(2)-microglobulin produced 2 bands with mol. wts corresponding to β(2)-microglobulin and the HLA-determinant polypeptide chain. After absorption of melanoma antisera with cross-linked foetal calf serum, erythrocytes, lymphocytes and fibroblasts, antibodies against 10 labelled antigens remained in the absorbed antisera. However, antibodies against 8 of these antigens were still detected after absorption of the melanoma antisera with melanoma cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6158972      PMCID: PMC2010400          DOI: 10.1038/bjc.1980.251

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Transplantability and antigenicity of two sublines of the TA3 tumor.

Authors:  B H Sanford; J F Codington; R W Jeanloz; P D Palmer
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

2.  Increased sialic acid density in surface glycoprotein of transformed and malignant cells--a general phenomenon?

Authors:  W P van Beek; L A Smets; P Emmelot
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

3.  Surface glycoproteins of normal and transformed cells: a difference determined by sialic acid and a growth-dependent sialyl transferase.

Authors:  L Warren; J P Fuhrer; C A Buck
Journal:  Proc Natl Acad Sci U S A       Date:  1972-07       Impact factor: 11.205

4.  Macromolecular components of the luminal fluid from the bovine uterus.

Authors:  G P Roberts; J M Parker
Journal:  J Reprod Fertil       Date:  1974-10

Review 5.  Regulation of antigenic expression.

Authors:  C A Apffel; J H Peters
Journal:  J Theor Biol       Date:  1970-01       Impact factor: 2.691

6.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

7.  The binding of sodium dodecyl sulphate to various proteins.

Authors:  R Pitt-Rivers; F S Impiombato
Journal:  Biochem J       Date:  1968-10       Impact factor: 3.857

8.  Increased antigenicity of glycoproteins after carbohydrase treatment.

Authors:  T B Quish; C F Lange
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1973-03

9.  Cell-surface glycoproteins of two sublines of the TA3 tumor.

Authors:  J F Codington; B H Sanford; R W Jeanloz
Journal:  J Natl Cancer Inst       Date:  1973-08       Impact factor: 13.506

10.  Externally disposed plasma membrane proteins. I. Enzymatic iodination of mouse L cells.

Authors:  A L Hubbard; Z A Cohn
Journal:  J Cell Biol       Date:  1975-02       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.